Chen Zhang
Peking University
41 Papers
163 Citations
Chen Zhang is an academic researcher from Peking University. The author has contributed to research in topics: Lymphoma & Diffuse large B-cell lymphoma. The author has an hindex of 10, co-authored 40 publications.
Chat about Author
Papers
A safe and potent anti-CD19 CAR T cell therapy
Zhitao Ying,Xue F. Huang,Xiaoyu Xiang,Yanling Liu,Xi Kang,Yuqin Song,Xiaokai Guo,Hanzhi Liu,Ning Ding,Tingting Zhang,Panpan Duan,Yufu Lin,Wen Zheng,Xiaopei Wang,Ningjing Lin,Meifeng Tu,Yan Xie,Chen Zhang,Weiping Liu,Lijuan Deng,Shunyu Gao,Lingyan Ping,Xuejuan Wang,Nina Zhou,Junqing Zhang,Yulong Wang,Songfeng Lin,Mierzhati Mamuti,Xueyun Yu,Lizhu Fang,Shuai Wang,Haifeng Song,Guan Wang,Lindsey Jones,Jun Zhu,Si-Yi Chen +35 more
TL;DR: Therapy with the new CD19-BBz(86) CAR T cells produces a potent and durable antilymphoma response without causing neurotoxicity or severe CRS, representing a safe and potent anti-CD19 CAR T cell therapy.
408
Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma.
Zhitao Ying,Ting He,Xiaopei Wang,Wen Zheng,Ningjing Lin,Meifeng Tu,Yan Xie,Lingyan Ping,Chen Zhang,Weiping Liu,Lijuan Deng,Feifei Qi,Yanping Ding,Xin-an Lu,Yuqin Song,Jun Zhu +15 more
TL;DR: It is suggested that 4-1BB is more beneficial for the clinical performance of CAR-T cells than CD28 in CD19-targeted B-NHL therapy, at least under the authors' manufacturing process.
149
A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type
Ningjing Lin,Yuqin Song,Wen Zheng,Meifeng Tu,Yan Xie,Xiaopei Wang,Lingyan Ping,Zhitao Ying,Chen Zhang,Lijuan Deng,Weiping Liu,Jun Zhu +11 more
TL;DR: CHOP-L chemotherapy in combination with radiotherapy is a safe and highly effective treatment for newly diagnosed ENKTL and the major adverse events were myelosuppression, liver dysfunction, and digestive tract toxicities.
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
Yizi He,Jiao Li,Ning Ding,Xiaogan Wang,Lijuan Deng,Yan Xie,Zhitao Ying,Weiping Liu,Lingyan Ping,Chen Zhang,Yuqin Song,Jun Zhu +11 more
TL;DR: Zhang et al. as mentioned in this paper investigated whether the combination of PKCβ inhibitor enzastaurin and BTK inhibitor ibrutinib has synergistic anti-tumor effects in DLBCL.
ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma
Yalu Liu,Xiaogan Wang,Lijuan Deng,Lingyan Ping,Yunfei Shi,Wen Zheng,Ningjing Lin,Xiaopei Wang,Meifeng Tu,Yan Xie,Weiping Liu,Zhitao Ying,Chen Zhang,Zhengying Pan,Xi Wang,Ning Ding,Yuqin Song,Jun Zhu +17 more
TL;DR: Findings suggest that ITK may be a novel candidate therapeutic target for the treatment of patients with ITK-expressing malignant T-cell lymphomas.